Literature DB >> 2867314

Patterns of progression in prostate cancer.

J E McNeal, D G Bostwick, R A Kindrachuk, E A Redwine, F S Freiha, T A Stamey.   

Abstract

Tumour volume was related to metastasis, seminal vesicle invasion, capsule invasion, and histological differentiation in a series of 100 unselected prostates with carcinoma removed at necropsy and 38 removed at radical prostatectomy. All these variables were highly inter-related. In both series, metastases were associated only with tumours larger than 4 ml, a volume attained by only 13% of the necropsy tumours. Loss of differentiation was strongly correlated with tumour volume, and only tumours of Gleason grade 4 or 5 had metastasised. It was concluded that the natural history of prostate cancer is highly predictable. The capacity to metastasise probably develops only in tumours which have grown much larger than 1 ml and acquired poorly differentiated areas as a manifestation of the phenomenon of tumour progression. The unusually low proportion of metastatic prostate cancer is readily explained by the large proportion of small-volume tumours in this organ.

Entities:  

Mesh:

Year:  1986        PMID: 2867314     DOI: 10.1016/s0140-6736(86)90715-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  50 in total

1.  Prostate cancers in men with low PSA levels--must we find them?

Authors:  H Ballentine Carter
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

2.  An MRI-compatible robotic system with hybrid tracking for MRI-guided prostate intervention.

Authors:  Axel Krieger; Iulian I Iordachita; Peter Guion; Anurag K Singh; Aradhana Kaushal; Cynthia Ménard; Peter A Pinto; Kevin Camphausen; Gabor Fichtinger; Louis L Whitcomb
Journal:  IEEE Trans Biomed Eng       Date:  2011-11       Impact factor: 4.538

3.  Tissue shrinkage after fixation with formalin injection of prostatectomy specimens.

Authors:  Sara Jonmarker; Alexander Valdman; Anna Lindberg; Magnus Hellström; Lars Egevad
Journal:  Virchows Arch       Date:  2006-08-15       Impact factor: 4.064

4.  Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer.

Authors:  Spyridon P Basourakos; John W Davis; Brian F Chapin; John F Ward; Curtis A Pettaway; Louis L Pisters; Neema Navai; Mary F Achim; Xuemei Wang; Hsiang-Chun Chen; Seungtaek Choi; Deborah Kuban; Patricia Troncoso; Sam Hanash; Timothy C Thompson; Jeri Kim
Journal:  BJU Int       Date:  2017-08-16       Impact factor: 5.588

Review 5.  Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1991-09-01       Impact factor: 8.262

6.  Development and Evaluation of an Actuated MRI-Compatible Robotic System for MRI-Guided Prostate Intervention.

Authors:  Axel Krieger; Sang-Eun Song; Nathan B Cho; Iulian Iordachita; Peter Guion; Gabor Fichtinger; Louis L Whitcomb
Journal:  IEEE ASME Trans Mechatron       Date:  2011-10-17       Impact factor: 5.303

7.  Diagnosis, prognosis and management of incidentally found prostate cancer.

Authors:  P J Davidson
Journal:  Urol Res       Date:  1993-01

8.  The changing pattern of prostate cancer in Nigerians: current status in the southeastern states.

Authors:  Paul D Ekwere; S N Egbe
Journal:  J Natl Med Assoc       Date:  2002-07       Impact factor: 1.798

9.  Dissemination of prostatic carcinoma: an autopsy study.

Authors:  F Lamothe; J Kovi; M Y Heshmat; E J Green
Journal:  J Natl Med Assoc       Date:  1986-11       Impact factor: 1.798

10.  Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.

Authors:  Kayvan R Keshari; Renuka Sriram; Mark Van Criekinge; David M Wilson; Zhen J Wang; Daniel B Vigneron; Donna M Peehl; John Kurhanewicz
Journal:  Prostate       Date:  2013-03-26       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.